AbbVie to Acquire Apogee Therapeutics for $10.9 Billion

Pharmaceutical giant AbbVie has announced its acquisition of biotechnology company Apogee Therapeutics in a deal valued at $10.9 billion. This strategic move is seen as part of AbbVie's goal to expand its portfolio and strengthen its presence, particularly in the respiratory disease area. The acquisition is expected to incorporate Apogee's advanced drug candidates and innovative research platform. Under the terms of the agreement, AbbVie will pay $75 per share in cash to Apogee shareholders. The offer represents a significant premium over Apogee's last closing price. The transaction is expected to close in the first quarter of 2025, subject to regulatory approvals and other customary closing conditions. Apogee Therapeutics is known for developing treatments for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Its most promising candidate, APG777, is currently in early-stage clinical trials. Through this acquisition, AbbVie aims to strengthen its R&D pipeline in respiratory diseases and enhance its competitive advantage in the market. This acquisition stands out as one of AbbVie's largest deals in recent years. The company has previously diversified its portfolio by acquiring various biotechnology firms. Analysts note that this move aligns with AbbVie's growth strategy and could create long-term shareholder value. This is not investment advice.